UPDATE: Actuate Therapeutics (ACTU) - A Great Science Project Doesn't Pay the Bills
The company announces a preclinical RAS combination initiative. The biology is sound, but the timing screams distraction.
The News
On March 9, 2026, Actuate Therapeutics announced the launch of an expanded research initiative. The plan is to evaluate their clinical-stage GSK-3beta inhibitor, elraglusib, in combination with emerging RAS-targeted therapies.
The Receipts (The Science)
From a purely biological perspective, this theoretically makes sense.
The Problem: The press release notes that a key barrier to RAS-targeted therapies is adaptive resistance and pathway reactivation. When you hit a tumor with a RAS inhibitor, the cancer immediately tries to build a bypass to survive.
The Elraglusib Hack: GSK-3 inhibition may act as a complementary strategy by suppressing those exact downstream bypass routes, specifically NF-kappaB-mediated survival signaling and MYC-driven transcriptional programs.
The Immune Bonus: RAS-mutant tumors, particularly pancreatic cancer, are highly resistant to the immune system. Actuate believes GSK-3beta inhibition can enhance antigen presentation, activate T cells and NK cells, and reduce T-cell exhaustion.
By simultaneously blocking the main engine (RAS) and shutting down the escape routes (GSK-3beta), Actuate is proposing a logical multi-modal therapeutic strategy.
